173 related articles for article (PubMed ID: 8991536)
1. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects.
Veltri S; Smith JW
Stem Cells; 1996 Mar; 14(2):164-76. PubMed ID: 8991536
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects.
Veltri S; Smith JW
Oncologist; 1996; 1(4):190-200. PubMed ID: 10387988
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
Mangi MH; Newland AC
Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
[TBL] [Abstract][Full Text] [Related]
5. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
6. Present and future clinical relevance of interleukin 3.
Gianella-Borradori A
Stem Cells; 1994; 12 Suppl 1():241-8. PubMed ID: 7696963
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
Meehan KR; Verma UN; Cahill R; Frankel S; Areman EM; Sacher RA; Foelber R; Rajagopal C; Gehan EA; Lippman ME; Mazumder A
Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
[TBL] [Abstract][Full Text] [Related]
8. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
10. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
11. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Kammula US; White DE; Rosenberg SA
Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
Atkins MB; Redman B; Mier J; Gollob J; Weber J; Sosman J; MacPherson BL; Plasse T
Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
15. Hematologic effects of interleukin-1 and interleukin-6.
Ruscetti FW
Curr Opin Hematol; 1994 May; 1(3):210-5. PubMed ID: 9371284
[TBL] [Abstract][Full Text] [Related]
16. The present and future of hematopoietic cytokines in clinical practice.
George MJ
Stem Cells; 1994; 12 Suppl 1():249-55. PubMed ID: 7696964
[TBL] [Abstract][Full Text] [Related]
17. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
20. [Interleukin-1 in cancer therapy].
Kawai K; Aihara K; Nakai S
Gan To Kagaku Ryoho; 1994 Mar; 21(4):573-80. PubMed ID: 8129405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]